C Number:	C20201A		
Lock Date:	07/24/2004		
Cage Range:	ALL		
Date Range:	ALL		
Reasons For Removal:	ALL		
Removal Date Range:	ALL		
Treatment Groups:	Include 001 0 NG/KG	Include 002 121 NG/KG	Include 003 760 NG/KG

FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED. IN OTHER TISSUES/ORGANS RATES ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.

Lung
Salivary Glands

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF TEF TRANSGENICS (TCDD)

FEMALE MICE

Organ	Morphology
Skin	Basal or Sq. Cell Carcinoma, Carcinoma, Basosq. Tumor (M or B), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepithelioma
	Squamous Cell Papilloma
	Squamous Cell Papilloma, Papilloma, Squamous Cell Carcinoma or Keratoacanthoma
Skin, Site of Application	Spindle Cell Carcinoma
	Squamous Cell Carcinoma
	Squamous Cell Papilloma
All Organs	Benign Tumors
	Malignant Tumors
	Malignant and Benign Tumors

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(TG.AC HEMI)
TERMINAL SACRIFICE AT 27 WEEKS

		Females	
DOSE	**0 NG/KG**	**121 NG/KG**	**760 NG/KG**

Skin
Basal or Sq. Cell Carcinoma, Carcinoma, Basosq. Tumor (M or B), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepithelioma

TUMOR RATES	#	#	#
OVERALL (a)	0/20 (0%)	2/20 (10%)	6/20 (30%)
POLY-3 RATE (b)	0/17.89	2/15.4	6/16.07
POLY-3 PERCENT (g)	0%	13%	37.3%
TERMINAL (d)	0/17 (0%)	1/12 (8%)	3/11 (27%)
FIRST INCIDENCE	---	163	143

STATISTICAL TESTS			
LIFE TABLE	P=0.003**	P=0.177	P=0.006**
POLY 3	P=0.003**	P=0.200	P=0.004**
POLY 1.5	P=0.004**	P=0.212	P=0.006**
POLY 6	P=0.002**	P=0.188	P=0.003**
LOGISTIC REGRESSION	P=0.006**	P=0.211	P=0.012*
COCH-ARM / FISHERS	P=0.008**	P=0.244	P=0.010**
ORDER RESTRICTED	P<0.001**	(e)	(e)
MAX-ISO-POLY-3	P=0.002**	(e)	(e)

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(TG.AC HEMI)
TERMINAL SACRIFICE AT 27 WEEKS

		Females	
DOSE	**0 NG/KG**	**121 NG/KG**	**760 NG/KG**
Skin **Squamous Cell Papilloma**			
TUMOR RATES	#	#	#
OVERALL (a)	0/20 (0%)	2/20 (10%)	5/20 (25%)
POLY-3 RATE (b)	0/17.89	2/15.4	5/16.07
POLY-3 PERCENT (g)	0%	13%	31.1%
TERMINAL (d)	0/17 (0%)	1/12 (8%)	2/11 (18%)
FIRST INCIDENCE	---	163	143
STATISTICAL TESTS			
LIFE TABLE	P=0.011*	P=0.177	P=0.015*
POLY 3	P=0.012*	P=0.200	P=0.014*
POLY 1.5	P=0.015*	P=0.212	P=0.017*
POLY 6	P=0.010**	P=0.188	P=0.011*
LOGISTIC REGRESSION	P=0.020*	P=0.211	P=0.028*
COCH-ARM / FISHERS	P=0.022*	P=0.244	P=0.024*
ORDER RESTRICTED	P=0.004**	(e)	(e)
MAX-ISO-POLY-3	P=0.007**	(e)	(e)

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(TG.AC HEMI)
TERMINAL SACRIFICE AT 27 WEEKS

		Females	
DOSE	**0 NG/KG**	**121 NG/KG**	**760 NG/KG**

Skin
Squamous Cell Papilloma, Papilloma, Squamous Cell Carcinoma or Keratoacanthoma

TUMOR RATES	#	#	#
OVERALL (a)	0/20 (0%)	2/20 (10%)	6/20 (30%)
POLY-3 RATE (b)	0/17.89	2/15.4	6/16.07
POLY-3 PERCENT (g)	0%	13%	37.3%
TERMINAL (d)	0/17 (0%)	1/12 (8%)	3/11 (27%)
FIRST INCIDENCE	---	163	143
STATISTICAL TESTS			
LIFE TABLE	P=0.003**	P=0.177	P=0.006**
POLY 3	P=0.003**	P=0.200	P=0.004**
POLY 1.5	P=0.004**	P=0.212	P=0.006**
POLY 6	P=0.002**	P=0.188	P=0.003**
LOGISTIC REGRESSION	P=0.006**	P=0.211	P=0.012*
COCH-ARM / FISHERS	P=0.008**	P=0.244	P=0.010**
ORDER RESTRICTED	P<0.001**	(e)	(e)
MAX-ISO-POLY-3	P=0.002**	(e)	(e)

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(TG.AC HEMI)
TERMINAL SACRIFICE AT 27 WEEKS

		Females	
DOSE	**0 NG/KG**	**121 NG/KG**	**760 NG/KG**
Skin, Site of Application			
Spindle Cell Carcinoma			
TUMOR RATES	#	#	#
OVERALL (a)	0/20 (0%)	0/20 (0%)	4/20 (20%)
POLY-3 RATE (b)	0/17.89	0/15.11	4/15.16
POLY-3 PERCENT (g)	0%	0%	26.4%
TERMINAL (d)	0/17 (0%)	0/12 (0%)	3/11 (27%)
FIRST INCIDENCE	---	---	155
STATISTICAL TESTS			
LIFE TABLE	P=0.003**	(e)	P=0.024*
POLY 3	P=0.004**	(e)	P=0.031*
POLY 1.5	P=0.005**	(e)	P=0.039*
POLY 6	P=0.003**	(e)	P=0.024*
LOGISTIC REGRESSION	P=0.005**	(e)	P=0.034*
COCH-ARM / FISHERS	P=0.008**	(e)	P=0.053
ORDER RESTRICTED	P=0.002**	(e)	(e)
MAX-ISO-POLY-3	P=0.005**	(e)	(e)

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(TG.AC HEMI)
TERMINAL SACRIFICE AT 27 WEEKS

		Females	
DOSE	**0 NG/KG**	**121 NG/KG**	**760 NG/KG**
Skin, Site of Application			
Squamous Cell Carcinoma			
TUMOR RATES	#	#	#
OVERALL (a)	0/20 (0%)	0/20 (0%)	9/20 (45%)
POLY-3 RATE (b)	0/17.89	0/15.11	9/15.59
POLY-3 PERCENT (g)	0%	0%	57.8%
TERMINAL (d)	0/17 (0%)	0/12 (0%)	7/11 (64%)
FIRST INCIDENCE	---	---	151
STATISTICAL TESTS			
LIFE TABLE	P<0.001**	(e)	P<0.001**
POLY 3	P<0.001**	(e)	P<0.001**
POLY 1.5	P<0.001**	(e)	P<0.001**
POLY 6	P<0.001**	(e)	P<0.001**
LOGISTIC REGRESSION	P<0.001**	(e)	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(TG.AC HEMI)
TERMINAL SACRIFICE AT 27 WEEKS

		Females	
DOSE	**0 NG/KG**	**121 NG/KG**	**760 NG/KG**
Skin, Site of Application			
Squamous Cell Papilloma			
TUMOR RATES	#	#	#
OVERALL (a)	1/20 (5%)	16/20 (80%)	19/20 (95%)
POLY-3 RATE (b)	1/17.89	16/17.25	19/20
POLY-3 PERCENT (g)	5.6%	92.8%	95%
TERMINAL (d)	1/17 (6%)	12/12 (100%)	10/11 (91%)
FIRST INCIDENCE	183 (T)	122	84
STATISTICAL TESTS			
LIFE TABLE	P<0.001**	P<0.001**	P<0.001**
POLY 3	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(TG.AC HEMI)
TERMINAL SACRIFICE AT 27 WEEKS

	Females		
DOSE	**0 NG/KG**	**121 NG/KG**	**760 NG/KG**
Stomach, Forestomach **Squamous Cell Papilloma**			
TUMOR RATES	#	#	#
OVERALL (a)	5/20 (25%)	4/20 (20%)	4/20 (20%)
POLY-3 RATE (b)	5/17.89	4/15.11	4/16.2
POLY-3 PERCENT (g)	28%	26.5%	24.7%
TERMINAL (d)	5/17 (29%)	4/12 (33%)	1/11 (9%)
FIRST INCIDENCE	183 (T)	183 (T)	129
STATISTICAL TESTS			
LIFE TABLE	P=0.530	P=0.571	P=0.563
POLY 3	P=0.535N	P=0.614N	P=0.567N
POLY 1.5	P=0.518N	P=0.568N	P=0.536N
POLY 6	P=0.560N	P=0.637	P=0.604N
LOGISTIC REGRESSION	P=0.588N	P=0.571	P=0.544N
COCH-ARM / FISHERS	P=0.510N	P=0.500N	P=0.500N
ORDER RESTRICTED	P=0.564N	(e)	(e)
MAX-ISO-POLY-3	P=0.568N	(e)	(e)

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(TG.AC HEMI)
TERMINAL SACRIFICE AT 27 WEEKS

		Females	
DOSE	**0 NG/KG**	**121 NG/KG**	**760 NG/KG**
Tooth **Odontogenic Tumor**			
TUMOR RATES	#	#	#
OVERALL (a)	6/20 (30%)	6/20 (30%)	2/20 (10%)
POLY-3 RATE (b)	6/18.15	6/16.02	2/15.29
POLY-3 PERCENT (g)	33.1%	37.5%	13.1%
TERMINAL (d)	5/17 (29%)	3/12 (25%)	1/11 (9%)
FIRST INCIDENCE	165	150	143
STATISTICAL TESTS			
LIFE TABLE	P=0.207N	P=0.388	P=0.291N
POLY 3	P=0.115N	P=0.535	P=0.173N
POLY 1.5	P=0.092N	P=0.573	P=0.143N
POLY 6	P=0.156N	P=0.501	P=0.220N
LOGISTIC REGRESSION	P=0.103N	P=0.534	P=0.163N
COCH-ARM / FISHERS	P=0.079N	P=0.634N	P=0.118N
ORDER RESTRICTED	P=0.105N	(e)	(e)
MAX-ISO-POLY-3	P=0.139N	(e)	(e)

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(TG.AC HEMI)
TERMINAL SACRIFICE AT 27 WEEKS

		Females	
DOSE	**0 NG/KG**	**121 NG/KG**	**760 NG/KG**
All Organs **Benign Tumors**			
TUMOR RATES	#	#	#
OVERALL (a)	6/20 (30%)	16/20 (80%)	19/20 (95%)
POLY-3 RATE (b)	6/17.89	16/17.25	19/20
POLY-3 PERCENT (g)	33.6%	92.8%	95%
TERMINAL (d)	6/17 (35%)	12/12 (100%)	10/11 (91%)
FIRST INCIDENCE	183 (T)	122	84
STATISTICAL TESTS			
LIFE TABLE	P<0.001**	P<0.001**	P<0.001**
POLY 3	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.002**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(TG.AC HEMI)
TERMINAL SACRIFICE AT 27 WEEKS

		Females	
DOSE	**0 NG/KG**	**121 NG/KG**	**760 NG/KG**
All Organs **Malignant Tumors**			
TUMOR RATES	#	#	#
OVERALL (a)	2/20 (10%)	1/20 (5%)	12/20 (60%)
POLY-3 RATE (b)	2/17.89	1/15.56	12/15.98
POLY-3 PERCENT (g)	11.2%	6.4%	75.1%
TERMINAL (d)	2/17 (12%)	0/12 (0%)	9/11 (82%)
FIRST INCIDENCE	183 (T)	150	151
STATISTICAL TESTS			
LIFE TABLE	P<0.001**	P=0.602N	P<0.001**
POLY 3	P<0.001**	P=0.549N	P<0.001**
POLY 1.5	P<0.001**	P=0.530N	P<0.001**
POLY 6	P<0.001**	P=0.568N	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P=0.526N	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500N	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(TG.AC HEMI)
TERMINAL SACRIFICE AT 27 WEEKS

		Females	
DOSE	**0 NG/KG**	**121 NG/KG**	**760 NG/KG**
All Organs **Malignant and Benign Tumors**			
TUMOR RATES	#	#	#
OVERALL (a)	11/20 (55%)	17/20 (85%)	20/20 (100%)
POLY-3 RATE (b)	11/18.15	17/17.42	20/20
POLY-3 PERCENT (g)	60.6%	97.6%	100%
TERMINAL (d)	10/17 (59%)	12/12 (100%)	11/11 (100%)
FIRST INCIDENCE	165	122	84
STATISTICAL TESTS			
LIFE TABLE	P<0.001**	P=0.003**	P<0.001**
POLY 3	P=0.003**	P=0.006**	P<0.001**
POLY 1.5	P=0.002**	P=0.009**	P<0.001**
POLY 6	P=0.004**	P=0.004**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	P=0.005**	P<0.001**
COCH-ARM / FISHERS	P=0.003**	P=0.041*	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)

LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.
(b)	Number of tumor-bearing animals/Poly-3 number
(d)	Observed incidence at terminal kill.
(f)	Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are theP-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
(e)	Value of Statistic cannot be computed.
(g)	Poly-3 adjusted lifetime tumor incidence.
(I)	Interim sacrifice
(T)	Terminal sacrifice
#	Tumor rates based on numbers of animals necropsied.
*	To the right of any statistical result, indicates significance at (P<=0.05).
**	To the right of any statistical result, indicates significance at (P<=0.01).
N	Indicates a negative trend for all tests
	Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.
	The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***